Literature DB >> 9112745

Molecular aspects of restitution: functions of trefoil peptides.

R Poulsom1, D E Begos, I M Modlin.   

Abstract

Healing of mucosal damage takes place in two phases: restitution of mucosal integrity and remodeling towards recreating the original glandular arrangements. These processes can be observed in several experimental rodent models: e.g., cryoprobe or NSAID-generated ulcers in the gastric or duodenal mucosa and following surgical resection of the small or large bowel. In some studies, it has been possible to detect changes in the expression of peptides, either in the reparative epithelium or adjacent to the damage, that may contribute to the healing processes. Trefoil peptides are expressed constitutively by epithelial cells in specific regions of the gastrointestinal tract, in association with mucins. Several studies have shown that trefoil peptide expression is enhanced at sites of damage in man and rat, and experimental evidence supports their active participation in the healing process. Recombinant trefoil peptides are able to enhance the rate of epithelial cell migration in vitro and are able to protect against indomethacin-induced damage in vivo, yet they do not depend upon TGF-beta for enhancing cell migration and do not appear to affect acid secretion. The mode of action of trefoil peptides appears to be receptor-mediated but is not simple. There is good evidence that there are interactions between members of the trefoil family and the EGF family that are beneficial for mucosal defense and repair. This raises the possibility that combining trefoil peptides with other growth factors or small molecules may be advantageous for treatment of ulceration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9112745      PMCID: PMC2588989     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  54 in total

1.  Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells.

Authors:  V Cavailles; M Garcia; H Rochefort
Journal:  Mol Endocrinol       Date:  1989-03

2.  Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coli.

Authors:  J F Prud'homme; A Jolivet; M F Pichon; J F Savouret; E Milgrom
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

3.  Expression of spasmolysin (FIM-A.1): an integumentary mucin from Xenopus laevis.

Authors:  F Hauser; E M Gertzen; W Hoffmann
Journal:  Exp Cell Res       Date:  1990-08       Impact factor: 3.905

4.  Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7).

Authors:  N Kida; T Yoshimura; K Mori; K Hayashi
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

5.  A new family of growth factor-like peptides. 'Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins).

Authors:  L Thim
Journal:  FEBS Lett       Date:  1989-06-19       Impact factor: 4.124

6.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

7.  Receptor binding of pancreatic spasmolytic polypeptide in intestinal mucosal cells and membranes.

Authors:  E K Frandsen
Journal:  Regul Pept       Date:  1988-01

8.  Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk.

Authors:  C Tomasetto; C Wolf; M C Rio; M Mehtali; M LeMeur; P Gerlinger; P Chambon; R Lathe
Journal:  Mol Endocrinol       Date:  1989-10

9.  The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein.

Authors:  A M Nunez; M Berry; J L Imler; P Chambon
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

10.  hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma.

Authors:  C Tomasetto; M C Rio; C Gautier; C Wolf; M Hareuveni; P Chambon; R Lathe
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

View more
  7 in total

Review 1.  Role of intestinal mucins in innate host defense mechanisms against pathogens.

Authors:  Poonam Dharmani; Vikas Srivastava; Vanessa Kissoon-Singh; Kris Chadee
Journal:  J Innate Immun       Date:  2008-10-08       Impact factor: 7.349

2.  Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma.

Authors:  Thaer Khoury; Krishdeep Chadha; Milind Javle; Kathleen Donohue; Charles Levea; Renuka Iyer; Haruhiko Okada; Hiroki Nagase; Dongfeng Tan
Journal:  Int J Gastrointest Cancer       Date:  2005

3.  Expression of intestinal trefoil factor, proliferating cell nuclear antigen and histological changes in intestine of rats after intrauterine asphyxia.

Authors:  Ling-Fen Xu; Jun Li; Mei Sun; Hong-Wei Sun
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

4.  Duodenal content reflux esophagitis in the rat: an animal model for the ulcer-associated cell lineage (UACL)?

Authors:  A M Hanby; M Pera; I Filipe; A Duranceau; N A Wright; M Pera; L Grande; R Poulsom
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

5.  Effects of recombinant human intestinal trefoil factor on trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  Jin Li; Rui Zhou; Wen-Cheng He; Bing Xia
Journal:  Mol Biol Rep       Date:  2010-12-12       Impact factor: 2.316

Review 6.  Epithelial restitution and wound healing in inflammatory bowel disease.

Authors:  Andreas Sturm; Axel U Dignass
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study.

Authors:  Takashi Kawai; Yu Takagi; Mari Fukuzawa; Tetsuya Yamagishi; Shinya Goto
Journal:  J Clin Biochem Nutr       Date:  2011-08-25       Impact factor: 3.114

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.